1. Abstract
Objectives Implanted cervical vagus nerve stimulation (VNS) is used to treat refractory epilepsy, depression, stroke sequelae and rheumatoid arthritis. The therapeutic efficacy of VNS is limited by stimulation- induced side effects, including hoarseness, coughing, and voice alteration. We quantified VNS-evoked laryngeal muscle activation (EMG; indicating side effects) and changes in heart rate (HR; proxy for activation of therapeutic fibers) in participants undergoing VNS implant surgery.
Methods We recruited adult participants (7F/3M) with treatment-resistant epilepsy who were receiving a new VNS implant (“acute”) or replacement of an implanted VNS pulse generator (“chronic”). During these procedures, we delivered VNS across pulsewidths (50, 250, and 1000 µs/phase) and stimulation amplitudes (0.05-28 mA) while recording laryngeal EMG and HR.
Results The median stimulation amplitudes to evoke 50% of maximal laryngeal EMG response were 1.32, 0.49, and 0.34 mA for pulsewidths of 50, 250, and 1000 µs/phase, respectively; thresholds were comparable between EMG electrodes placed endotracheally and subcutaneously. The median stimulation amplitudes to cause a 10% decrease in HR were 13.39 and 3.53 mA at 50 and 250 µs/phase, respectively—i.e., ~6 to 63x higher than the 50% EMG thresholds. We did not observe a difference in EMG or HR responses between sexes, acute/chronic, or stimulation polarities. For each subject in the chronic implant group, clinician- selected stimulation amplitudes were higher than the 50% EMG thresholds and lower than the 10% HR thresholds.
Conclusions Thresholds to evoke bradycardia were ~2x higher than clinician-selected stimulation amplitudes. This indicates that the target fibers of VNS for epilepsy may be larger diameter than those projecting to the heart. Alternatively, the therapeutic effect in refractory epilepsy may be evoked with less fiber activation than is required to produce bradycardia.
Competing Interest Statement
Warren M Grill receives compensation as a member of the NeuroEdge Advisory Board for LivaNova PLC. Derek G Southwell is a consultant or has received speaking honoria from NeuroPace, NeuroOne and AlphaOmega.
Clinical Trial
NCT05395026
Funding Statement
This study was funded by the Duke Coulter Translational Partnership
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Duke University Health System gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Typo in author name. Kevin Mohsenisan, corrected to Kevin Mohsenian.
Data Availability
All data produced in the present study are available upon reasonable request to the authors, at this time.
